지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Background & Significance: Therapeutic efficacy of Argatroban, a direct thrombin inhibitor, in acute ischemic
stroke is not known yet. The aim of this study was to determine the safety and effect of argatroban in early phase
of acute ischemic stroke. M e t h o d: This study included 106 patients with acute thrombotic and non-lacunar
ischemic stroke who presented no later than 48 hours. Argatroban was administered by intravenous infusion at 60
mg/day for the first 2 days and then at 10 mg/day twice daily for the subsequent 5 days. Control group received
aspirin (300 mg/days) for 7 days. We estimated the subjects’neurologic deficits and functional outcomes by using
National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (MRS) prior to argatroban infusion
and other therapy, on day 1 and 7 the initiation of the therapy. Results: The mean scores of NIHSS and MRS were
17.00±7.4 and 4.12±1.02 on admission, 13.21±8.21 and 3.39±1.48 on the first day after argatroban therapy,
and 9.41±7.58 and 2.75±1.55 on 7th day after therapy, respectively. In control group, the mean scores of
NIHSS and MRS on the admission day, firstt and 7th hospital days were 17.46±6.59 and 4.12±1.00, 16.72±
8.42 and 3.84±1.44, 15.08±8.34 and 3.54±1.49, respectively. There were no bleeding complications in all
groups. Conclusion: The results of this study suggest that argatroban therapy resulted in more improvement of
neurologic deficits than control group in acute ischemic stroke (p<0.01, difference of NIHSS and MRS between
argatroban and control group). Therefore, we suggest that argatroban treatment is an effective and safe drug for
the early phase treatment of acute ischemic stroke.
(Korean Journal of Stroke 2005;7(2): 191~196)
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Treatment for Patients with Acute Ischemic Stroke Presenting beyond Six Hours of Ischemic Symptom Onset : Effectiveness of Intravenous Direct Thrombin Inhibitor, Argatroban
대한신경외과학회지
2010 .01
-
가토대퇴정맥에서 미세혈관문합시 Argatroban의 국소세척 및 전신투여가 혈전형성에 미치는 영향
대한구강악안면외과학회지
2005 .01
-
허혈뇌졸중의 중증도와 장애 정도에 대한 뇌졸중 위험인자와의 연관성
대한뇌졸중학회지
2012 .01
-
Stroke Update 2009: 급성기 뇌졸중 치료
대한뇌졸중학회지
2009 .01
-
Hemispheric Differences in Ischemic Stroke: Is Left-Hemisphere Stroke More Common?
Journal of Clinical Neurology
2013 .01
-
Polymorphism of Nitric Oxide Synthase 1 Affects the Clinical Phenotypes of Ischemic Stroke in Korean Population
Annals of Rehabilitation Medicine
2016 .01
-
Organizing Healthcare for Optimal Acute Ischemic Stroke Treatment
Journal of Clinical Neurology
2020 .01
-
뇌졸중 환자의 임상적 검사NIHSS(National Institutes of Health Stroke Scale)와 기능적 예후와의 상관관계
대한물리치료사학회지
2002 .01
-
Blood Pressure in Acute Ischemic Stroke
Journal of Clinical Neurology
2016 .01
-
Multimodal Therapy for Patients with Acute Ischemic Stroke : Outcomes and Related Prognostic Factors
대한신경외과학회지
2009 .01
-
Stroke: Morbidity, Risk Factors, and Care in Taiwan
대한뇌졸중학회지
2014 .01
-
대학병원에 입원한 허혈뇌졸중 환자들의 10년간 임상특성의 시계열 변동 분석(1999~2008년)
대한뇌졸중학회지
2010 .01
-
Risk Factors and Biomarkers of Ischemic Stroke in Cancer Patients
대한뇌졸중학회지
2014 .01
-
Smoking is Not a Good Prognostic Factor following First-Ever Acute Ischemic Stroke
대한뇌졸중학회지
2015 .01
-
2019 Update of the Korean Clinical Practice Guidelines of Stroke for Endovascular Recanalization Therapy in Patients with Acute Ischemic Stroke
대한뇌졸중학회지
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0